Skip to main content
SpringerLink
Log in

Withdrawal of benzodiazepines in primary care usually requires careful tapering of the dosage

  • Practical Issues and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs 2009; 23(1): 19–34

    Article  PubMed  CAS  Google Scholar 

  2. O’Brien CP. Benzodiazepine use, abuse and dependence. J Clin Psychiatry 2005; 66Suppl. 2: 28–33

    PubMed  Google Scholar 

  3. Taylor S, McCracken CF, Wilson KC, et al. Extent and appropriateness of benzodiazepine use: results from an elderly urban community. Br J Psychiatry 1998; 173: 433–8

    Article  PubMed  CAS  Google Scholar 

  4. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs 1994; 1: 377–87

    Article  Google Scholar 

  5. Kripke DF, Klauber MR, Wingard DL, et al. Mortality hazard associated with prescription of hypnotics. Biol Psychiatry 1998; 43(9): 687–93

    Article  PubMed  CAS  Google Scholar 

  6. Siriwardena AN, Qureshi Z, Gibson S, et al. GP’s attitudes to benzodiazepine and “z-drug” prescribing: a barrier to implementation of evidence and guidance on hypnotics. Br J Gen Pract 2006; 56(533): 964–7

    PubMed  Google Scholar 

  7. National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia. London: National Institute for Clinical Excellence, 2004 Apr: Technology appraisal no. 77

    Google Scholar 

  8. Estivill E, Bove A, Garcia-Borreguero D, et al. Consensus on drug treatment, definition and diagnosis for insomnia. Clin Drug Invest 2003; 23(6): 351–85

    Article  CAS  Google Scholar 

  9. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 57. London: BMJ Publishing Group Ltd and RPS Publishing, 2009 Mar

    Google Scholar 

  10. Hughes LM, Holden JD, Tree AM. Audit as a method of reducing benzodiazepine prescribing in general practice. J Clin Eff 1997; 2: 79–82

    Google Scholar 

  11. Bashir K, King M, Ashworth M. Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines. Br J Gen Pract 1994; 44(386): 408–12

    PubMed  CAS  Google Scholar 

  12. Towle I, Adams J. A novel, pharmacist-led strategy to reduce the prescribing of benzodiazepines in Paisley. Pharm J 2006; 276: 136–8

    Google Scholar 

  13. Cormack MA, Sweeney KG, Hughes J, et al. Evaluation of an easy cost-effective strategy for cutting benzodiazepine use in general practice. Br J Gen Pract 1994; 44(378): 5–8

    PubMed  CAS  Google Scholar 

  14. Gorgels WJM, Oude Voshar RC, Mol AJ, et al. Predictors of discontinuation of benzodiazepine prescription after sending a letter to long-term benzodiazepine users in family practice. Fam Pract 2006; 23(1): 65–72

    Article  PubMed  CAS  Google Scholar 

  15. Baker R, Farooqi A, Tait C, et al. Randomised controlled trial of reminders to enhance the impact of audit in general practice on management of patients who use benzodiazepines. Qual Health Care 1997; 6(1): 14–8

    Article  PubMed  CAS  Google Scholar 

  16. Dollman WB, LeBlanc VT, Stevens LO, et al. Achieving a sustained reduction in benzodiazepine use through implementation of an area-wide multi-strategic approach. J Clin Pharm Ther 2005; 30(5): 425–32

    Article  PubMed  CAS  Google Scholar 

  17. Jørgensen VRK. An approach to reduce benzodiazepine and cyclopyrrolone use in general practice: a study based on a Danish population. CNS Drugs 2007; 21(11): 947–55

    Article  PubMed  Google Scholar 

  18. Denis C, Fatseas M, Lavie E, et al. Pharmacological interventions for benzodiazepine mono-dependence in outpatient settings. Cochrane Database Syst Rev 2006; (3): CD005194

    PubMed  Google Scholar 

  19. Strom Jr JG, Kalu AU. Formulation and stability of diazepam suspension compounded from tablets. Am J Hosp Pharm 1986 Jun; 43(6): 1489–91

    PubMed  CAS  Google Scholar 

  20. Sips JHM, Pessers JW. Quit without suffering [in Dutch; online]. Available from URL: http://www.knmp.nl/download-bestanden/fpz-prijs/fpz-prijs-2009/stoppen-zonder-lijden/projectbeschrijving-stoppen-zonder-lijden.pdf [Accesssed 2009 Jun 10]

  21. Saxon L, Hjemdahl P, Hiltunen AJ, et al. Effects of flumazenil in the treatment of benzodiazepine withdrawal: a double-blind pilot study. Psychopharmacol 1997; 131(2): 153–60

    Article  CAS  Google Scholar 

  22. Gerra G, Zaimovic A, Giusti F, et al. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized placebo-controlled study. Addict Biol 2002; 7(4): 385–95

    Article  PubMed  CAS  Google Scholar 

  23. Nutt DJ, Glue P, Lawson C, et al. Flumazenil provocation of panic attacks. Arch Gen Psychiatry 1990; 47(10): 9176–25

    Article  Google Scholar 

  24. Mintzer MZ, Stoller KB, Griffiths RR. A controlled study of flumazenil-precipitated withdrawal in low-dose benzodiazepoine users. Psychopharmacology 1999; 147(2): 200–9

    Article  PubMed  CAS  Google Scholar 

  25. Bernik MA, Gorenstein C, Veira Filho AHG. Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users. J Psychopharmacol 1998; 12(2): 146–50

    Article  PubMed  CAS  Google Scholar 

  26. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999; 19(6 Suppl. 2): 17–22S

    Article  Google Scholar 

  27. Gosselin P, Ladouceur R, Morin CM, et al. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol 2006; 74(5): 908–19

    Article  PubMed  Google Scholar 

  28. Oude Voshaar RC, Gorgels WJ, Mol AJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive-behavioural therapy: three-condition, randomised controlled trial. Br J Psychiatry 2003; 182: 498–504

    Article  Google Scholar 

  29. Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol Med 1984; 14(4): 937–40

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Withdrawal of benzodiazepines in primary care usually requires careful tapering of the dosage. Drugs Ther. Perspect 25, 23–26 (2009). https://doi.org/10.2165/0042310-200925090-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925090-00007

Search

Navigation